organ transplant
Natera Reports 52 Percent Spike in Q1 Revenues, Raises Full-Year Guidance
The company beat analysts' estimates on the top and bottom lines with growth driven by increased testing volumes and improvements in average test selling price.
Craig-Hallum Upgrades CareDx to Buy
Analyst Bill Bonello said CareDx has substantially de-risked its business and could benefit from Medicare coverage of kidney transplant surveillance testing.
Craig-Hallum Initiates Coverage of Natera With Buy Rating
Analyst Bill Bonello noted growth potential across Natera's markets, along with potential risks related to reimbursement, competition, and profitability.
Eurofins Acquires Ascend Clinical
Eurofins said the deal helps support its efforts to expand within the transplant testing and renal care space.
CareDx Eyes Wider Coverage, Adoption of Transplant Tests Despite Medicare Billing Article Impact
Premium
Adapting to the coverage decision put a dent in test volumes, but the firm has implemented needed changes and expects to see gains toward the end of the year.
Apr 20, 2022
Nov 24, 2021
NGeneBio Gets CE-IVD Mark for HLA Typing Assay
Oct 29, 2021
Jul 13, 2021
Natera Inks Distribution Deal With TomaLab for Italy
Feb 25, 2021
Feb 24, 2021